Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Share-based Compensation (2016 - 2025)

Avanos Medical's Share-based Compensation history spans 11 years, with the latest figure at $3.8 million for Q4 2024.

  • For Q4 2024, Share-based Compensation fell 5.0% year-over-year to $3.8 million; the TTM value through Dec 2024 reached $14.4 million, down 10.56%, while the annual FY2025 figure was $12.6 million, 8.7% down from the prior year.
  • Share-based Compensation for Q4 2024 was $3.8 million at Avanos Medical, up from $2.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.1 million in Q3 2022 and bottomed at $2.5 million in Q1 2020.
  • The 5-year median for Share-based Compensation is $3.6 million (2021), against an average of $3.5 million.
  • The largest YoY upside for Share-based Compensation was 88.24% in 2020 against a maximum downside of 40.48% in 2020.
  • A 5-year view of Share-based Compensation shows it stood at $3.2 million in 2020, then fell by 6.25% to $3.0 million in 2021, then soared by 33.33% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then decreased by 5.0% to $3.8 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Share-based Compensation are $3.8 million (Q4 2024), $2.6 million (Q3 2024), and $4.0 million (Q4 2023).